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and Big ET-1 levels, and tissue expression of ET-1 in patients with
ductal carcinoma of the breast. Methods: Peripheral venous blood
samples were collected prior to diagnostic biopsy from women with
suspicious non-palpable mammographic lesions. Plasma ET-1 and Big
ET-1 levels were determined in 30 patients with IDC, 30 with DCIS and
30 with benign lesions (controls), by performing ELISA. ET-1 and VEGF
tissue expression was immunohistochemically determined. Potential
correlationswith histological grade, hormone receptor status, Her2/neu
ampliﬁcation, tumor size, lymph node involvement and disease stage
were investigated in IDC. Results: Big ET-1 plasma levels were signif-
icantly higher in IDC and DCIS patients compared to controls (p b 0.001
and p b 0.01, respectively). No signiﬁcant differences in ET-1 levels
were observed between the three groups. Moderate to strong IHC
staining for ET-1 was observed in 3/29 and 7/23 IDC and DCIS patients,
respectively. VEGF was signiﬁcantly expressed in 8/27 and 8/23 IDC
and DCIS patients, respectively. In IDC, plasma and tissue expression
of ET-1 and plasma expression of Big ET-1 did not correlate with any of
the analyzed clinicopathological characteristics or VEGF tissue expres-
sion. Conclusions: Plasma levels of Big ET-1 were a more sensitive
indicator of ET-1 deregulation than those of ET-1 in our study. Our
results support the potential clinical application of Big ET-1 as a breast
cancer biomarker.
doi:10.1016/j.lfs.2013.12.047
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Background: Endothelin-1 (ET-1) acts via two G-protein-coupled
receptors, ETA and ETB. Overexpressed ET-1 and ETA in colorectal
cancer (CRC) promote tumour growth and progression. Aim: To
investigate (1) ETA and ETB distribution in normal and cancer tissues
from patients with CRC and (2) determine ETA and ETB localisation to
cell types and tissue structures. Methods: ETA and ETB distribution was
determined using in vitro autoradiographywith competitive inhibition,
using receptor antagonists (BQ123, ZD4054, BQ788) on normal and
cancer tissues resected from patients with CRC (N= 8). Immunohis-
tochemistry (IHC) conﬁrmed ETA and ETB expression and identiﬁed
associated cells/structures. ETA distribution was also investigated by
quantum dots (QDs) conjugated to BQ123 (ETA-antagonist). Results: In
normal bowel epithelium, ETA was observed closer to the luminal
surface and ETB towards the muscularis mucosa/lamina propria. There
was greater ETA than ETB binding in CRC. Both cancer and normal
tissues demonstrated strongest binding to stromal cells, particularly
ﬁbroblasts (IHC). QD-BQ123 demonstrated an ETA punctate pattern in
stromal areas surrounding epithelial cells; and an ETA increase in CRC
compared to normal. Conclusions: ET-1 binds strongly to CRC stromal
structures, with ETA greater than ETB, and is consistent with ET-1
signalling contributing to tumourigenesis. Within normal tissue, dif-
ferential ETA and ETB distribution (luminal versus muscularis mucosa/
lamina propria) has not been reported previously. This may relate to
trophic, growth arrest and differentiation signalling. This study dem-
onstrates the effective, novel use of receptor-antagonist-conjugated
QDs; reveals possible ET-1 roles in normal tissue; and provides further
evidence for the potential therapeutic use of ETA antagonists as CRC
adjuvant treatment.
doi:10.1016/j.lfs.2013.12.048
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Background: The endothelin A receptor (ETA)mediates tumourigenic
signals in colorectal cancer (CRC). The ETA ligand, endothelin-1 (ET-1),
stimulates not only cancer cells but also surrounding ﬁbroblasts andmay
promote the creation of a supporting tumour stroma. Aim: To identify
ET-1 regulated genes associated with oncogenic pathways in colonic
ﬁbroblasts. Methods:Micro-array analysis following 4 h ET-1 stimulation
of colonic ﬁbroblast strains (isolated from patients undergoing resection
for CRC, n = 4) identiﬁed differentially expressed genes (n= 19) at
signiﬁcant levels. Three were investigated further: COLXI, AML-1, and
EGFR (collagen type-XI; acute myeloid leukemia-1; epidermal growth-
factor receptor). Quantitative RT-PCR (qRT-PCR) and immunoblotting
evaluated AML-1 and COLX expression levels, following treatment with
ET-1 and/or receptor antagonists (ETA: BQ123, ZD4054; ETB: BQ788).
ETA and ETB regulation of EGFR was investigated by gene silencing
(siRNA); these assays and ET-1 regulation of EGFR over 24 h were
evaluated by qRT-PCR. Results: ET-1 stimulated expression of AML-1 and
COLXI at both gene (N1.5-fold; p b 0.01) and protein (p b 0.05) levels;
stimulation was inhibited by ETA, but not by ETB, antagonism (AML-1:
75.1–77.1% by BQ123, ZD4054; COLXI: 65.1% by ZD4054; p b 0.05). EGFR
expression demonstrated a biphasic increase at 4 h and 24 h (3.8-fold;
4.5-fold). Silencing ETA, but not ETB, returned EGFR levels to control.
Conclusions: ETA antagonism has potential for targeting oncogenic
pathways: AML-1 is linked to c-Jun N-terminal kinase which inhibits
apoptosis/promotes proliferation; and abnormal TGF-β (transforming
growth-factor-beta) signalling. COLXI is linked to CRC tumourogenesis.
The ET-1-stimulated biphasic EGFR response and ETA antagonism have
not been reported before in CRC. These ﬁndings identify mechanisms
by which ETA promotes tumourigenesis and support addition of ZD4054
to existing EGFR antagonism therapy.
doi:10.1016/j.lfs.2013.12.049
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In human medicine there have been many studies reporting the
importance of evaluating serum ET-1 or big ET-1 in various diseases
as a clinical marker, especially related to pulmonary hypertension
and several tumors. In veterinary medicine, however, few studies
have been performed on the clinical importance of serum ET-1 or
big ET-1. In this study we explored the feasibility of using the serum
big ET-1 as a clinical marker in dogs with various cardiopulmonary
and neoplastic diseases. Pulmonary hypertension was diagnosed in
dogs by echocardiography based on the velocity of tricuspid valve
regurgitation. Serum big ET-1 and NT-pro BNP concentrations in these
dogsweremeasuredby ELISA and comparedwith those of healthy dogs.
Serum big ET-1 concentration in dogs with various neoplastic diseases
was also assessed and compared. Our results showed a signiﬁcant
increase of serum big ET-1 in dogs with pulmonary hypertension,
lung tumor and hemangiosarcoma when compared to normal dogs.
No signiﬁcant difference was observed in NT-pro BNP concentration
between healthy and pulmonary hypertension dogs. Although further
studies are necessary, these ﬁndings point to the potential of serum big
ET-1 as a clinical marker in canine pulmonary hypertension and for
some tumor types.
doi:10.1016/j.lfs.2013.12.050
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A 56-year-old man developed sudden dyspnoea after resection of
choroidal melanoma in his left eyeball. Worsening hypoxia required
intensive treatment, including percutaneous cardiopulmonary support.
On contrast-enhanced computed tomography there was no evidence
of either thrombi in the pulmonary arteries or obvious lung diseases.
A Swan–Ganz catheter showed increased mean pulmonary arterial
pressure and no elevation of pulmonary capillary wedge pressure.
These ﬁndings were consistent with a diagnosis of pulmonary arterial
hypertension. Because reports have described a signiﬁcant relation-
ship between melanoma and endothelin (ET)-1, we hypothesized that
a substantial amount of ET-1 had been released from malignant mela-
noma cells during resection, thus triggering the pulmonary hyperten-
sive crisis in our patient. The patient fully recovered after intensive
treatment and administration of the endothelin receptor antagonist
bosentan. The success of bosentan treatment, along with an extremely
high level of ET-1 on pathologic analysis, conﬁrmed our hypothesis
regarding an increase in plasma ET-1 level — 9.60 pg/mL (normal
range b 2.3 pg/mL).
doi:10.1016/j.lfs.2013.12.051
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Objective: The primary objective of the Phase I study was to assess
the safety and tolerability of SPI-1620 administered to patients with
recurrent or progressive carcinomawhohad failed all standard therapy.
Secondary objectives were to assess PK and PD proﬁles of SPI-1620,
and to identify the optimum dose of SPI-1620 to be used in future
Phase II studies. The pharmacokinetic properties of SPI-1620 will be
presented. Methods: Eligible patients received SPI-1620 by intravenous
infusion over 1 min in an accelerated dose escalation scheme. SPI-1620
doses ranged from 0.5 μg/m2 to 15.1 μg/m2. Serial blood samples were
collected from each patient prior to infusion (0 min) and at pre-
speciﬁed intervals from the start of the infusion. Human plasma
samples were analyzed by a validated HPLC–MS/MS method. Descrip-
tive PK parameters were determined by standard model independent
methods based on the concentration–time data of each subject. Results
& conclusion: The highest concentration of SPI-1620 was achieved
by the end of infusion. SPI-1620 C max increased proportionally as a
function of SPI-1620 dosewhile the AUC (0–T) increased in amore than
dose proportional manner. The SPI-1620 T 1/2 was short and ranged
from 4.38 min to 8.29 min. SPI-1620 had a low systemic clearance and
small VD (approximately equal to the intravascular volume).
doi:10.1016/j.lfs.2013.12.052
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The epithelial–mesenchymal transition (EMT) is known to play a
crucial role in the aggressiveness of epithelial ovarian cancer (EOC),
contributing to chemoresistance and cancer stem cell populations. In
this tumor, the endothelin (ET)-1/endothelin A receptor (ETAR) axis,
by regulating EMT and invasion, endows EOC cells with an increased
chemoresistance. Here we examined whether β-arrestin-1 (β-arr1)
can act as a nuclear hub orchestrating nuclear signaling in ETAR-
driven EMT and chemoresistance. A signiﬁcant higher expression of
β-arr1 and ET-1/ETAR and the stronger presence of β-arr1 in the
nuclear compartment upon ETAR activation are present in chemo-
resistant cells, compared to sensitive cells. In the nuclei, β-arr1
robustly interacts with β-catenin to form a nuclear complex localized
on the ET-1 promoter region, leading to transcription of ET-1, dem-
onstrating that β-arr1 drives the positive inter-regulation of ET-1
itself. This autocrine circuit is involved in β-arr1-driven appearance
of EMT features and acquisition of stem-cell like properties. More-
over, at functional level, chemoresistant cells, with high nuclear
β-arr1, display higher invasive potential and increased resistance
to chemotherapeutic drugs. These effects were inhibited by ET-1
receptor blockade with macitentan, or by β-arr1 nuclear mutant.
Abstracts e9
